Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus
NEWS	18	JAN 12	Match STN Content and Features to Your Information Needs, Quickly and Conveniently

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:30:49 ON 14 JAN 2010

of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10583419.str





chain nodes :
8 26 27 28
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
chain bonds :
6-8 8-9 12-15 22-26 26-27 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 23-24
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 9-10 9-14 10-11 11-12 12-13 12-15 13-
14 15-16 15-20 16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 22-26
23-24
normalized bonds :
26-27 26-28

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 26:CLASS 27:CLASS
28:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:31:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 25 TO ITERATE

100.0% PROCESSED 25 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 200 TO 800
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 13:32:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 748 TO ITERATE

100.0% PROCESSED 748 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

STRUCTURE FILE UPDATES: 13 JAN 2010 HIGHEST RN 1202161-01-0
DICTIONARY FILE UPDATES: 13 JAN 2010 HIGHEST RN 1202161-01-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information

on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10583419.str



chain nodes :
8
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
chain bonds :
6-8 8-9 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 23-24
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 9-10 9-14 10-11 11-12 12-13 12-15 13-
14 15-16 15-20 16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 23-24

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 13:33:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1095 TO ITERATE

100.0% PROCESSED 1095 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 19915 TO 23885
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> s l4 ful
FULL SEARCH INITIATED 13:34:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21544 TO ITERATE

100.0% PROCESSED 21544 ITERATIONS 45 ANSWERS
SEARCH TIME: 00.00.01

L6 45 SEA SSS FUL L4

FILE COVERS 1907 - 14 Jan 2010 VOL 152 ISS 3
FILE LAST UPDATED: 12 Jan 2010 (20100112/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l6
L7 24 L6

=> d abs fbib fhitstr 1-24

L7 ANSWER 1 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Fifty one quinoline-3-carboxylic acids I (R1 = c-Pr, t-Bu, 2,4-F2C6H3; R2R3N = 17 secondary amines) were synthesized from 1,3-dichloro-2-methylbenzene and evaluated for in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB), and Mycobacterium smegmatis (MC2). Among the synthesized compds., I (R1 = c-Pr, R2R3N = 1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) was found to be the most active compound in vitro with a MIC value of 0.39 μM against MTB. Against MDR-TB, compound I (R1 = c-Pr, R2R3N = 2-carboxy-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl) was found to be the most active with a MIC value of 0.09 μM. Generally, quinoline-3-carboxylic acids I (R1 = c-Pr) were most active and most were tested for their cytotoxicity in a mammalian Vero cell line.

AN 2009:254822 CAPLUS Full-text
DN 150:472531
TI Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids
AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Chandraseakaran, Yogesh; Yogeeswari, Perumal; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, India
SO Archiv der Pharmazie (Weinheim, Germany) (2009), 342(2), 100-112
CODEN: ARPMAS; ISSN: 0365-6233
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 150:472531
IT 1146300-42-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (amino)(oxo)quinolinecarboxylic acids and their antimycobacterial structure-activity relationships)
RN 1146300-42-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methyl-6-nitro-4-oxo- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Various 1-(substituted)-1,4-dihydro-6-nitro-4-oxo-7-(sub-secondary amino)-quinoline-3-carboxylic acids were synthesized from 2,4-dichlorobenzoic acid by six step synthesis. The compds. were evaluated for antimycobacterial in vitro and in vivo against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the 48 synthesized compds., compound I was found to be the most active compound in vitro with MIC of 0.08 and 0.16 μM against MTB and MDR-TB, resp. In the in vivo animal model, compound I decreased the bacterial load in lung and spleen tissues with 2.78 and 4.15-log 10 protections, resp., at the dose of 50 mg/kg body weight

AN 2009:5914 CAPLUS Full-text
DN 150:259917
TI Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids
AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Yogeeswari, Perumal; Sriram, Dharmarajan; China, Arnab; Nagaraja, Valakunja
CS Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, 333031, India
SO European Journal of Medicinal Chemistry (2009), 44(1), 345-358
CODEN: EJMCA5; ISSN: 0223-5234
PB Elsevier Masson SAS
DT Journal
LA English
OS CASREACT 150:259917
IT 1119087-07-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of nitroquinolinolonecarboxylic acids via nitration of dichlorobenzoic acid followed by alkylation, cyclization with amines and amination with secondary amines, and their antimycobacterial

activity)
RN 1119087-07-8 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
AB Thirty four novel 7-fluoro/nitro-1,2-dihydro-5-oxo-8-(sub)-5H-thiazolo[3,2-a]quinoline- 4-carboxylic acids were synthesized from 2,4-dichlorobenzoic acid and 2,4-dichloro-5-fluoroacetophenone by multi step reaction, evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the synthesized compds., 8-[6-[[(1,1-dimethylethoxy)carbonyl]amino]-3-azabicyclo[3.1.0]hex-3-yl]- 1,2-dihydro-7-nitro-5-oxo-5H-thiazolo[3,2-a]quinoline-4- carboxylic acid (10q) was the most active compound in vitro with MIC of 0.08 μM and <0.08 μM against MTB and MDR-TB resp. Compound 10q was 4.5 and >570 times more potent than isoniazid against MTB and MDR-TB resp. In the in vivo animal model 10q decreased the bacterial load in lung and spleen tissues with 2.51 and 3.71-log10 protections resp. at the dose of 50 mg/kg body weight
AN 2008:1027779 CAPLUS Full-text
DN 149:462071
TI Synthesis, antimycobacterial activities and phototoxic evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic acid derivatives
AU Dinakaran, Murugesan; Senthilkumar, Palaniappan; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Medicinal Chemistry (2008), 4(5), 482-491
CODEN: MCEHAJ; ISSN: 1573-4064
PB Bentham Science Publishers Ltd.
DT Journal
LA English
OS CASREACT 149:462071
IT 1070905-93-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, antimycobacterial activities and phototoxic evaluation of thiazoloquinoline-carboxylic acid derivs.)
RN 1070905-93-9 CAPLUS
CN 5H-Thiazolo[3,2-a]quinoline-4-carboxylic acid, 8-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-7-fluoro-1,2-dihydro-5-oxo- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
AB On the basis of our recent findings that 6-aminoquinolones inhibit the HIV Tat-mediated transactivation, we have designed a broad series of derivs. identifying novel potent agents such as the 6-desfluoroquinolones 24 (HM12) and 27 (HM13), which showed pronounced anti-HIV activity in acutely, chronically, and latently HIV-1 infected cell cultures. We demonstrate here that highly potent mols. can be obtained by optimizing the substituent in the various positions of the quinolone nucleus.
AN 2008:1015905 CAPLUS Full-text
DN 149:346718
TI Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones
AU Tabarrini, Oriana; Massari, Serena; Daelemans, Dirk; Stevens, Miguel; Manfroni, Giuseppe; Sabatini, Stefano; Balzarini, Jan; Cecchetti, Violetta; Pannecouque, Christophe; Fravolini, Arnaldo
CS Dipartimento di Chimica e Tecnologia del Farmaco, Universita di Perugia, Perugia, 06123, Italy
SO Journal of Medicinal Chemistry (2008), 51(17), 5454-5458
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 149:346718
IT 1056878-77-3P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and SAR of anti-HIV 6-desfluoroquinolones)
RN 1056878-77-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 6-amino-1,4-dihydro-1-methyl-4-oxo-7-[4-(2-pyridinyl)-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Various 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid derivs. were synthesized from 2-aminothiophenol by a five-step reaction, evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multidrug resistant Mycobacterium tuberculosis (MDR-TB), and Mycobacterium smegmatis (MC2), and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the thirty-four synthesized compds., the most active compound (I) had MIC of 0.18 and 0.08 μM in vitro against MTB and MTR-TB, resp. Compound I was found to be 2 and 570 times more potent than isoniazid against MTB and MDR-TB, resp. In the in-vivo animal model 7l decreased the bacterial load in lung and spleen tissues with 2.78 and 3.12 - log 10 protections, resp., at the dose of 50 mg/kg body weight

AN 2008:413955 CAPLUS Full-text
DN 148:580321
TI Antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid derivs.
AU Dinakaran, Murugesan; Senthilkumar, Palaniappan; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Bioorganic & Medicinal Chemistry (2008), 16(6), 3408-3418
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal

LA English
OS CASREACT 148:580321
IT 1028203-05-5P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antimycobacterial activities of novel 2-(sub)-3-fluoro/nitro-5,12-dihydro-5-oxobenzothiazolo[3,2-a]quinoline-6-carboxylic acid derivs.)
RN 1028203-05-5 CAPLUS
CN 5H-Benzothiazolo[3,2-a]quinoline-6-carboxylic acid, 2-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-3-fluoro-5-oxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Several newer 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2- a]quinoline-3-carboxylic acids (10-11a-q) were synthesized from 3,4-difluoro aniline and 3-fluoro-4-nitro aniline by 9-step synthesis. The compds. were evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multidrug-resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis as well as being tested for their ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the synthesized compds., 7-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)-6-nitro-4-oxo-4H-[1,3]thiazeto[3,2- a]quinoline-3-carboxylic acid (I) was the most active

compound in vitro, with MICs of 0.09 μM and <0.09 μM against MTB and MDR-TB, resp. I was 4-fold and >506-fold more potent than isoniazid against MTB and MDR-TB, resp. In the in vivo animal model, I decreased the bacterial load in lung and spleen tissues by 30% and 42%, resp., at a dose of 50 mg/kg body weight

AN 2008:366343 CAPLUS Full-text

DN 148:580312

TI Antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid

AU Murugesan, Dinakaran; Palaniappan, Senthilkumar; Perumal, Yogeeswari; Arnab, China; Valakunja, Nagaraja; Sriram, Dharmarajan

CS Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science (BITS), Pilani, 333031, India

SO International Journal of Antimicrobial Agents (2008), 31(4), 337-344
CODEN: IAAGEA; ISSN: 0924-8579

PB Elsevier B.V.

DT Journal

LA English

IT 1027327-22-5P
RL: BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acids)

RN 1027327-22-5 CAPLUS

CN 1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-6-fluoro-4-oxo- (CA INDEX NAME)



L7 ANSWER 7 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

AB Thirty-four newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids were synthesized from 1,2,3,4-tetrafluoro benzene and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase. Among the synthesized compds., 7-(1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydroisoquinolin-2(1H)-yl)- 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxoquinoline-3- carboxylic acid (13n) was found to

be the most active compound in vitro with MIC of 0.16 and 0.33 μM against MTB and MDR-TB, resp. In the in vivo animal model 13n decreased the bacterial load in lung and spleen tissues with 2.54 and 2.92 - log10 protections, resp., at the dose of 50 mg/kg body weight Compound 13n also inhibited the supercoiling activity of mycobacterial DNA gyrase with IC50 of 30.0 μg/mL.

AN 2008:339599 CAPLUS Full-text
DN 148:444657
TI Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids
AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Banerjee, Debjani; Devakaram, Ruth Vandana; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Bioorganic & Medicinal Chemistry (2008), 16(5), 2558-2569
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:444657
IT 1018937-82-0P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids)
RN 1018937-82-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Thirty derivs. of 7-oxo-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acids were synthesized from 2,3,4,5-tetrafluoro benzoic acid and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB), and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from mycobacteria. Among them, compound I was found to be the most active compound in vitro with MIC99 of 0.19 μM and 0.09 μM against MTB and MTR-TB, resp. In the in vivo animal model also the same compound decreased the bacterial load in lung and spleen tissues with 1.91 and 2.91 - log 10 protections, resp., at the dose of 50 mg/kg body weight Compound II was found to be the most active in the inhibition of the supercoiling activity of DNA gyrase with an IC50 of 10.0 μg/mL. The results demonstrate the potential and importance of developing new oxazino quinolone derivs. against mycobacterial infections.

AN 2008:151718 CAPLUS Full-text
DN 148:355718

TI Novel ofloxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation

AU Dinakaran, Murugesan; Senthilkumar, Palaniappan; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India

SO Bioorganic & Medicinal Chemistry Letters (2008), 18(3), 1229-1236
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:355718

IT 1012310-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of oxazinoquinolinecarboxylic acids starting from tetrafluorobenzoic acid using heterocyclization and amination with secondary amines as key steps, and their antibacterial activity as DNA gyrase inhibitor and toxicity)

RN 1012310-46-1 CAPLUS
CN 7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, ethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

AB Fifty-one 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acids were synthesized and evaluated for antimycobacterial in vitro and in vivo against Mycobacterium tuberculosis H37Rv (MTB), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the synthesized compds., 1-tert-butyl-1,4-dihydro-7-(4,4-dimethyloxazolidin-3-yl)-6-nitro-4-oxo-1,8- naphthyridine-3-carboxylic acid (10q) is the most active compound in vitro with an MIC of 0.1 μM against MTB and MDR-TB and was 3 and 455 times more potent than isoniazid against MTB and MDR-TB, resp. In the in vivo animal model 10q decreased the bacterial load in lung and spleen tissues with 2.39 and 3.89-log10protections, resp., at the dose of 50 mg/kg body weight

AN 2007:1215588 CAPLUS Full-text
DN 148:78912
TI Antimycobacterial Activities of Novel 1-(Cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic Acid
AU Sriram, Dharmarajan; Senthilkumar, Palaniappan; Dinakaran, Murugesan; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Journal of Medicinal Chemistry (2007), 50(24), 6232-6239
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 148:78912
IT 960314-15-2P, 7-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo-1,8-naphthyridine-3-carboxylic Acid
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acids)
RN 960314-15-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB Certain 1H-imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolines, 1H-imidazo[4,5-c][1,5]naphthyridines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]naphthyridines, and 1H-imidazo[4,5-c]pyridines substituted at the 1- and 2-positions [I; X1 = CH2, NH, O; R1 = cyclopentyl, cyclohexyl, cyclopentyl, etc.; R2 = NH2, Me, CH2(alkyl), etc.; R3 and R4 taken together form (un)substituted fused benzene or pyridine ring], useful as immunomodulators, were prepared E.g., a multi-step synthesis of II, starting from 4-hydroxy-3-nitro[1,5]naphthyridine, was given. Pharmaceutical compns. containing compds. I, methods of making these compds., and methods of use of these compds. as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

AN 2007:729369 CAPLUS Full-text
DN 147:143425
TI Preparation of substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines for inducing cytokine biosynthesis
IN Merrill, Bryon A.; Haraldson, Chad A.; Prince, Ryan B.; Manske, Karl J.; Kshirsagar, Tushar A.; Heppner, Philip D.; Dressel, Luke T.; Krepski, Larry R.; Rice, Michael J.
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 209pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007075468	A1	20070705	WO 2006-US48017	20061215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

			US 2005-751392P	P	20051216
AU 2006332000	A1	20070705	AU 2006-332000		20061215
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
CA 2634017	A1	20070705	CA 2006-2634017		20061215
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
EP 1968587	A1	20080917	EP 2006-845602		20061215

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
JP 2009519955	T	20090521	JP 2008-545861		20061215
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
IN 2008DN04982	A	20080808	IN 2008-DN4982		20080610
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
ZA 2008005105	A	20090624	ZA 2008-5105		20080611
			US 2005-751392P	P	20051216
KR 2008077982	A	20080826	KR 2008-714349		20080613
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
CN 101330916	A	20081224	CN 2006-80047491		20080616
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
MX 2008007864	A	20090304	MX 2008-7864		20080616
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215
NO 2008002757	A	20080904	NO 2008-2757		20080618
			US 2005-751392P	P	20051216
			WO 2006-US48017	W	20061215

OS MARPAT 147:143425

IT 943629-90-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines for inducing cytokine biosynthesis)

RN 943629-90-1 CAPLUS

CN 1H-Imidazo[4,5-c]quinoline, 2-(ethoxymethyl)-7-(4-phenyl-1-piperidinyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 943629-89-8

CMF C30 H36 N4 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

AB Substituted pyridines and pyrimidines and compns. contg. them are claimed for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotizing agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. Example compound 4-(4-tert-butylphenyl)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)pyridin-2(1H)-one was prepared by reacting 4-(4-tert-butylphenyl)pyridin-2(1H)-one and 1-bromo-3,4-(ethylenedioxy)benzene. No biol. data is given in the patent.

AN 2007:701137 CAPLUS Full-text
DN 147:118146

TI Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands for treatment of pain, inflammatory conditions, and other diseases

IN Chen, Ning; Nishimura, Nobuko; Norman, Mark H.; Ognyanov, Vassil I.; Ognyanov, Diana
PA Amgen, Inc., USA

SO U.S. Pat. Appl. Publ., 51 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070149513	A1	20070628	US 2006-644226	20061222
				US 2005-753994P P	20051223
	WO 2007076104	A1	20070705	WO 2006-US49208	20061222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2005-753994P P 20051223

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:118146

IT 942947-13-9P, 1-(Quinolin-7-yl)-4-[4-(trifluoromethyl)phenyl]piperidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands for treatment of pain, inflammatory conditions, and other diseases)

RN 942947-13-9 CAPLUS

CN 2-Piperidinone, 1-(7-quinolinyl)-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L7 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

AB Quadruplex nucleotide sequences and methods for identifying interacting mols. are provided. The quadruplex sequences comprise C-rich or G-rich sequences from human genomic DNA and may conform to the motif ((G3+)N1-7)3G3+ or ((C3+)N1-7)3C3+, where "3+" is three or more nucleotides, C is cytosine, G is guanine, and N is any nucleotide. The method for identifying quinoline or porphyrin derivs. that bind to human nucleic acid containing a quadruplex structure or displace a protein from a nucleic acid comprises: (1) contact the nucleic acid and a compound that binds to the nucleic acid with a test mol.; and (2) detecting the amount of the compound bound or not bound to the nucleic acid. The test mol. is identified as a mol. that binds to the nucleic acid containing the human nucleotide sequence when less of the compound binds to the nucleic acid in the presence of the test mol. than in the absence of the test mol. The invention also identifies 1450 quinolone derivs. that bind to quadruplex DNA or RNA sequences. Identifying modulators of nucleic acid synthesis is achieved in a system containing template nucleic acid, primer oligonucleotides, and DNA polymerase or RNA polymerase.

AN 2007:538440 CAPLUS Full-text

DN 147:3133

TI Targeting quadruplex sequences in human nucleic acids by identifying interacting quinoline and porphyrin derivatives

IN O'Brien, Sean; Siddiqui-Jain, Adam

PA Cylene Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 219pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2007056113	A2	20070518	WO 2006-US42906		20061102
	WO 2007056113	A9	20090305			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
				US 2005-732531P	P	20051102
				US 2005-735686P	P	20051110
	US 20090291437	A1	20091126	US 2008-92557		20080731
				US 2005-732531P	P	20051102
				US 2005-735686P	P	20051110
				WO 2006-US42906	W	20061102

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 783361-00-2
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(targeting quadruplex sequences in human nucleic acids by identifying interacting quinoline and porphyrin derivs.)

RN 783361-00-2 CAPLUS

CN 3H-Benzo[b]pyrido[3,2,1-kl]phenoxazine-2-carboxamide, 6-(4-cyano-4-phenyl-1-piperidinyl)-5-fluoro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted (hetero)aryl which may be monocyclic or fused with a single or multiple ring and optionally containing a heteroatom; R5 = H, OR2, alkyl, alkenyl, etc.] or II [V, A, X, Z, and U are as defined above; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful in screening and for inducing apoptosis. Over forty synthetic examples showed the synthesis of intermediates and target compds. E.g., a multi-step synthesis of the amide III, starting from 2,3,4,5-tetrafluorobenzoic acid, was given. The title compds. were tested in various tests. For example, they were tested in a stop assay, a high throughput, first-pass screen detecting drugs that bind to and stabilize the target G-quadruplex. E.g., the compound III exhibits approx. 400x selectivity for the c-Myc quadruplex relative to pUC

18 plasmid DNA. III was also tested for antitumor activity (biol. data given). The pharmaceutical composition comprising the compds. I or II is disclosed.

AN 2006:120542 CAPLUS Full-text

DN 144:212787

TI Preparation of substituted quinobenzoxazine analogs as antitumor agents

IN Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence

PA Cylene Pharmaceuticals, Inc., USA

SO U.S. Pat. Appl. Publ., 558 pp., Cont.-in-part of U.S. Ser. No. 903,975. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20060029950	A1	20060209	US 2005-106909		20050415
	US 7507727	B2	20090324			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
				US 2004-903975	A2	20040730
	US 7141565	B1	20061128	US 2004-821243		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	US 20050085468	A1	20050421	US 2004-903975		20040730
	US 7354916	B2	20080408			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
	AU 2005325210	A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	CA 2575547	A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	WO 2006078317	A1	20060727	WO 2005-US26977		20050729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
	EP 1773346	A1	20070418	EP 2005-856890		20050729

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
JP 2008508311	T	20080321		JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
ZA 2005008093	A	20080430		ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
US 20080261963	A1	20081023		US 2008-13961		20080114
US 7612063	B2	20091103				
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328

PATENT FAMILY INFORMATION:

FAN 2004:902098

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004091504	A2	20041028	WO 2004-US11108		20040407
	WO 2004091504	A3	20060105			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
AU 2004229489	A1	20041028		AU 2004-229489		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
CA 2521810	A1	20041028		CA 2004-2521810		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
EP 1610759	A2	20060104		EP 2004-759406		20040407

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407

BR 2004009105	A	20060425	BR 2004-9105		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
CN 1809572	A	20060726	CN 2004-80014351		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
JP 2006522827	T	20061005	JP 2006-509898		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
NZ 543006	A	20090331	NZ 2004-543006		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
RU 2353621	C2	20090427	RU 2005-134206		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
MX 2005010776	A	20060525	MX 2005-10776		20051006
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
ZA 2005008093	A	20080430	ZA 2005-8093		20051006
			US 2003-461271P	P	20030407
KR 2006029210	A	20060405	KR 2005-719057		20051007
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
NO 2005004669	A	20051114	NO 2005-4669		20051011
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
IN 2005KN02147	A	20070727	IN 2005-KN2147		20051031
			US 2003-461271P	P	20030407
			WO 2004-US11108	W	20040407
US 20080261963	A1	20081023	US 2008-13961		20080114
US 7612063	B2	20091103			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A3	20040407

				US 2006-390810	A3	20060328
	IN 2009KN02283	A	20090710	IN 2009-KN2283		20090619
				US 2003-461271P	P	20030407
				WO 2004-US11108	W	20040407
				IN 2005-KN2147	A3	20051031

FAN 2005:349002

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20050085468	A1	20050421	US 2004-903975		20040730
	US 7354916	B2	20080408			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
	US 7141565	B1	20061128	US 2004-821243		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	US 20060029950	A1	20060209	US 2005-106909		20050415
	US 7507727	B2	20090324			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
				US 2004-903975	A2	20040730
	AU 2005325210	A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	CA 2575547	A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	WO 2006078317	A1	20060727	WO 2005-US26977		20050729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
	EP 1773346	A1	20070418	EP 2005-856890		20050729
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	JP 2008508311	T	20080321	JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415

			WO 2005-US26977	W	20050729
ZA 2005008093	A	20080430	ZA 2005-8093		20051006
			US 2003-461271P	P	20030407
US 20060229303	A1	20061012	US 2006-390810		20060328
US 7326702	B2	20080205			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A3	20040407
US 20070043039	A1	20070222	US 2006-431602		20060510
US 7381720	B2	20080603			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A3	20040407
US 20080261963	A1	20081023	US 2008-13961		20080114
US 7612063	B2	20091103			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A3	20040407
			US 2006-390810	A3	20060328

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 144:212787; MARPAT 144:212787

IT 783361-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-00-2 CAPLUS

CN 3H-Benzo[b]pyrido[3,2,1-kl]phenoxazine-2-carboxamide, 6-(4-cyano-4-phenyl-1-piperidinyl)-5-fluoro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-oxo- (CA INDEX NAME)

PAGE 1-A





OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a prepn. of quinoline and [1,8]naphthyridine derivs. of formula I [wherein: A is (cyclo)alkylene, alk(en/yn)ylene, or heteroarylene, etc.; Q is N, C(OH), or heteroalkyl, etc.; X is N, CH, C(F), C(OH), or C(NH2), etc.; Y is N, CH, or C(OMe), etc.; Z and L are independently (CH2)1-3; R1 is H, halogen, or NH2, etc.; R2 is H, F, or Cl; R3 is H, (cyclo)alkyl, alk(en/yn)yl, or (hetero)aryl, etc.; R4 is a derivative of oxazole, furan, or isoxazole], useful as antimicrobial agents (no biol. data). The invention compds. are effective against a variety of multi-drug resistant bacteria. For instance, [1,8]naphthyridine derivative II was prepared via amination of 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4- oxo-[1,8]naphthyridine-3-carboxylic acid by piperidine derivative III with a yield of 64%.

AN 2005:570890 CAPLUS Full-text
DN 143:97344
TI A preparation of quinoline and [1,8]naphthyridine derivatives, useful as antibiotics
IN Hubschwerlen, Christian; Specklin, J. L.; Baeschlin, Daniel Kaspar; Sigwalt, Christine; Mueller, Stefan; Cappi, Michael
PA Morphochem A.-G., Germany
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005058888	A2	20050630	WO 2004-EP14500	20041220
	WO 2005058888	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,

MR, NE, SN, TD, TG

				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
EP 1557416	A1	20050727		EP 2004-1506		20040123
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
AU 2004299278	A1	20050630		AU 2004-299278		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
CA 2549675	A1	20050630		CA 2004-2549675		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
EP 1709044	A2	20061011		EP 2004-804099		20041220
EP 1709044	B1	20080716				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS						
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
CN 1898238	A	20070117		CN 2004-80038072		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
BR 2004017193	A	20070306		BR 2004-17193		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
JP 2007516263	T	20070621		JP 2006-544382		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
ZA 2006004180	A	20071128		ZA 2006-4180		20041220
				US 2003-530822P	P	20031218
AT 401326	T	20080815		AT 2004-804099		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
PT 1709044	E	20081027		PT 2004-804099		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
ES 2310299	T3	20090101		ES 2004-804099		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
RU 2371443	C2	20091027		RU 2006-125510		20041220
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
IN 2006MN00693	A	20070323		IN 2006-MN693		20060613
				US 2003-530822P	P	20031218
				WO 2004-EP14500	W	20041220
MX 2006006769	A	20061219		MX 2006-6769		20060615
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
KR 2007067003	A	20070627		KR 2006-714403		20060718
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
HK 1090647	A1	20080905		HK 2006-112470		20061113

				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220
	US 20080027040	A1	20080131	US 2007-583419		20070928
				US 2003-530822P	P	20031218
				EP 2004-1506	A	20040123
				WO 2004-EP14500	W	20041220

PATENT FAMILY INFORMATION:

FAN 2004:965064

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004096221	A1	20041111	WO 2004-EP3650		20040406
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
	AU 2004233557	A1	20041111	AU 2004-233557		20040406
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	CA 2529347	A1	20041111	CA 2004-2529347		20040406
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	EP 1620098	A1	20060201	EP 2004-725909		20040406
	EP 1620098	B1	20080611			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	BR 2004009955	A	20060425	BR 2004-9955		20040406
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	CN 1832746	A	20060913	CN 2004-80018679		20040406
	CN 100544719	C	20090930			
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	JP 2006526577	T	20061124	JP 2006-505018		20040406
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
				WO 2004-EP3650	W	20040406
	ZA 2005009147	A	20070328	ZA 2005-9147		20040406
				US 2003-466945P	P	20030430
	AT 397930	T	20080715	AT 2004-725909		20040406
				US 2003-466945P	P	20030430
				US 2003-530822P	P	20031218
	ES 2308171	T3	20081201	ES 2004-725909		20040406
				US 2003-466945P	P	20030430

			US 2003-530822P	P	20031218
NZ 543757	A	20090228	NZ 2004-543757		20040406
			US 2003-466945P	P	20030430
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406
RU 2351335	C2	20090410	RU 2005-137032		20040406
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406
ZA 2006004180	A	20071128	ZA 2006-4180		20041220
			US 2003-530822P	P	20031218
MX 2005011654	A	20051215	MX 2005-11654		20051028
			US 2003-466945P	P	20030430
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406
IN 2005MN01254	A	20060505	IN 2005-MN1254		20051110
			US 2003-466945P	P	20030430
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406
HK 1078806	A1	20080829	HK 2006-101647		20060208
			US 2003-466945P	P	20030430
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406
US 20070155714	A1	20070705	US 2007-554732		20070105
			US 2003-466945P	P	20030430
			US 2003-530822P	P	20031218
			WO 2004-EP3650	W	20040406

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:97344; MARPAT 143:97344

IT 856677-21-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoline and [1,8]naphthyridine derivs. useful as antibiotics)

RN 856677-21-9 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]ethynyl]-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

AN 2005:349002 CAPLUS Full-text
DN 142:373851
TI Preparation of substituted quinobenzoxazine analogs as antitumor agents
IN Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terence
PA USA
SO U.S. Pat. Appl. Publ., 453 pp., Cont.-in-part of U.S. Ser. No. 821,243.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 20050085468	A1	20050421	US 2004-903975		20040730
US 7354916	B2	20080408			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A2	20040407
US 7141565	B1	20061128	US 2004-821243		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
US 20060029950	A1	20060209	US 2005-106909		20050415
US 7507727	B2	20090324			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A2	20040407
			US 2004-903975	A2	20040730

AU 2005325210		A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
CA 2575547		A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
WO 2006078317		A1	20060727	WO 2005-US26977		20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
EP 1773346		A1	20070418	EP 2005-856890		20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
JP 2008508311		T	20080321	JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
ZA 2005008093		A	20080430	ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
US 20060229303		A1	20061012	US 2006-390810		20060328
US 7326702		B2	20080205			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
US 20070043039		A1	20070222	US 2006-431602		20060510
US 7381720		B2	20080603			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
US 20080261963		A1	20081023	US 2008-13961		20080114
US 7612063		B2	20091103			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328

PATENT FAMILY INFORMATION:

FAN 2004:902098

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	WO 2004091504	A2	20041028	WO 2004-US11108	20040407
	WO 2004091504	A3	20060105		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
	AU 2004229489	A1	20041028	AU 2004-229489	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	CA 2521810	A1	20041028	CA 2004-2521810	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	EP 1610759	A2	20060104	EP 2004-759406	20040407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	BR 2004009105	A	20060425	BR 2004-9105	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	CN 1809572	A	20060726	CN 2004-80014351	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	JP 2006522827	T	20061005	JP 2006-509898	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112
				US 2003-532727P	P 20031223
				WO 2004-US11108	W 20040407
	NZ 543006	A	20090331	NZ 2004-543006	20040407
				US 2003-461271P	P 20030407
				US 2003-463171P	P 20030415
				US 2003-519535P	P 20031112

				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	RU 2353621	C2	20090427	RU 2005-134206		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	MX 2005010776	A	20060525	MX 2005-10776		20051006
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	ZA 2005008093	A	20080430	ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
	KR 2006029210	A	20060405	KR 2005-719057		20051007
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	NO 2005004669	A	20051114	NO 2005-4669		20051011
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	IN 2005KN02147	A	20070727	IN 2005-KN2147		20051031
				US 2003-461271P	P	20030407
				WO 2004-US11108	W	20040407
	US 20080261963	A1	20081023	US 2008-13961		20080114
	US 7612063	B2	20091103			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328
	IN 2009KN02283	A	20090710	IN 2009-KN2283		20090619
				US 2003-461271P	P	20030407
				WO 2004-US11108	W	20040407
				IN 2005-KN2147	A3	20051031

FAN 2006:120542

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20060029950	A1	20060209	US 2005-106909		20050415
	US 7507727	B2	20090324			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
				US 2004-903975	A2	20040730
	US 7141565	B1	20061128	US 2004-821243		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	US 20050085468	A1	20050421	US 2004-903975		20040730

US 7354916		B2	20080408			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
AU 2005325210		A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
CA 2575547		A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
WO 2006078317		A1	20060727	WO 2005-US26977		20050729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
EP 1773346		A1	20070418	EP 2005-856890		20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
JP 2008508311		T	20080321	JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
ZA 2005008093		A	20080430	ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
US 20080261963		A1	20081023	US 2008-13961		20080114
US 7612063		B2	20091103			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 142:373851

IT 783361-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-00-2 CAPLUS

CN 3H-Benzo[b]pyrido[3,2,1-kl]phenoxazine-2-carboxamide, 6-(4-cyano-4-phenyl-1-piperidinyl)-5-fluoro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to quinobenzoxazines analogs I [V = H, halo, NR1R2; A = H, F, N(R1)2; Z = O, S, NR1, CH2; U = OR2, NR1R2; X = OR2, NR1R2, halo, azido, SR2; R1 and R2 in NR1R2 may form a double bond or ring; R1 = H, alkyl; R2 = H, alkyl or alkenyl optionally containing one or more non-adjacent heteroatoms selected from N, O, and S, and optionally substituted with a carbocyclic or heterocyclic ring; or R2 = (un)substituted heterocyclyl, (hetero)aryl; W = (un)substituted 1,2-benzo, pyrido, naphthaleno, etc.; and pharmaceutically acceptable salts, esters and prodrugs thereof] which are useful for ameliorating a cell disorder such as cancer. Forty-six synthetic examples showed the synthesis of intermediates. E.g., a 4-step synthesis of the fluoroacid II, starting from potassium Et malonate and 2,3,4,5-tetrafluorobenzoyl chloride, was given. Such prepared fluoroacids were reacted with amines to provide compds. I which were then tested in MTS assay

and for inhibition of c-myc mRNA. E.g., the compound III showed 50% inhibition of c-myc mRNA levels at 4 μM. The compds. I were tested for antitumor activity in mice (biol. data given for representative compds. I). The compds. I were also claimed as useful for ameliorating a microbial infection.

AN 2004:902098 CAPLUS Full-text
DN 141:395565
TI Preparation of substituted quinobenzoxazine analogs as antitumor agents
IN Whitten, Jeffrey P.; Schwaebe, Michael; Siddiqui-Jain, Adam; Moran, Terrance
PA Cyclene Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004091504	A2	20041028	WO 2004-US11108		20040407
	WO 2004091504	A3	20060105			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	AU 2004229489	A1	20041028	AU 2004-229489		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	CA 2521810	A1	20041028	CA 2004-2521810		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	EP 1610759	A2	20060104	EP 2004-759406		20040407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				WO 2004-US11108	W	20040407
	BR 2004009105	A	20060425	BR 2004-9105		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223

			WO 2004-US11108	W	20040407
CN 1809572	A	20060726	CN 2004-80014351		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
JP 2006522827	T	20061005	JP 2006-509898		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
NZ 543006	A	20090331	NZ 2004-543006		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
RU 2353621	C2	20090427	RU 2005-134206		20040407
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
MX 2005010776	A	20060525	MX 2005-10776		20051006
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
ZA 2005008093	A	20080430	ZA 2005-8093		20051006
			US 2003-461271P	P	20030407
KR 2006029210	A	20060405	KR 2005-719057		20051007
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
NO 2005004669	A	20051114	NO 2005-4669		20051011
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			WO 2004-US11108	W	20040407
IN 2005KN02147	A	20070727	IN 2005-KN2147		20051031
			US 2003-461271P	P	20030407
			WO 2004-US11108	W	20040407
US 20080261963	A1	20081023	US 2008-13961		20080114
US 7612063	B2	20091103			
			US 2003-461271P	P	20030407
			US 2003-463171P	P	20030415
			US 2003-519535P	P	20031112
			US 2003-532727P	P	20031223
			US 2004-821243	A3	20040407
			US 2006-390810	A3	20060328
IN 2009KN02283	A	20090710	IN 2009-KN2283		20090619
			US 2003-461271P	P	20030407
			WO 2004-US11108	W	20040407
			IN 2005-KN2147	A3	20051031

PATENT FAMILY INFORMATION:

FAN 2005:349002

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20050085468	A1	20050421	US 2004-903975		20040730
	US 7354916	B2	20080408			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
	US 7141565	B1	20061128	US 2004-821243		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	US 20060029950	A1	20060209	US 2005-106909		20050415
	US 7507727	B2	20090324			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
				US 2004-903975	A2	20040730
	AU 2005325210	A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	CA 2575547	A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	WO 2006078317	A1	20060727	WO 2005-US26977		20050729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
	EP 1773346	A1	20070418	EP 2005-856890		20050729
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	JP 2008508311	T	20080321	JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	ZA 2005008093	A	20080430	ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
	US 20060229303	A1	20061012	US 2006-390810		20060328

	US 7326702	B2	20080205			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
	US 20070043039	A1	20070222	US 2006-431602		20060510
	US 7381720	B2	20080603			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
	US 20080261963	A1	20081023	US 2008-13961		20080114
	US 7612063	B2	20091103			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328

FAN 2006:120542

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20060029950	A1	20060209	US 2005-106909		20050415
	US 7507727	B2	20090324			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
				US 2004-903975	A2	20040730
	US 7141565	B1	20061128	US 2004-821243		20040407
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
	US 20050085468	A1	20050421	US 2004-903975		20040730
	US 7354916	B2	20080408			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A2	20040407
	AU 2005325210	A1	20060727	AU 2005-325210		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	CA 2575547	A1	20060727	CA 2005-2575547		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
	WO 2006078317	A1	20060727	WO 2005-US26977		20050729

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
EP 1773346		A1	20070418	EP 2005-856890		20050729
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR						
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
JP 2008508311		T	20080321	JP 2007-523846		20050729
				US 2004-903975	A	20040730
				US 2005-106909	A	20050415
				WO 2005-US26977	W	20050729
ZA 2005008093		A	20080430	ZA 2005-8093		20051006
				US 2003-461271P	P	20030407
US 20080261963		A1	20081023	US 2008-13961		20080114
US 7612063		B2	20091103			
				US 2003-461271P	P	20030407
				US 2003-463171P	P	20030415
				US 2003-519535P	P	20031112
				US 2003-532727P	P	20031223
				US 2004-821243	A3	20040407
				US 2006-390810	A3	20060328

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:395565

IT 783361-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted quinobenzoxazine analogs as antitumor agents)

RN 783361-00-2 CAPLUS

CN 3H-Benzo[b]pyrido[3,2,1-kl]phenoxazine-2-carboxamide, 6-(4-cyano-4-phenyl-1-piperidinyl)-5-fluoro-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-3-oxo- (CA INDEX NAME)

PAGE 1-A





OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB New antiprotozoals active against Philasterides dicentrarchi, the causative agent of scuticociliatosis in farmed turbot and Black Sea bass-bream, have been synthesized and tested. The most active compds. possess a piperazine ring, generally N-bonded to the heterocycle, and are 1,8-naphthyridine, pyridothienopyrimidine, and pyridothienotriazine derivs. The pyridothienotriazine I (R1 = 4-methylpiperidino, R2 = 1-piperazinyl) presents the same activity (LD = 0.8/1.5 mg L-1) as the well-known antiparasitics niclosamide and oxyclozanide.

AN 2003:236103 CAPLUS Full-text

DN 139:197457

TI Piperazine N-substituted naphthyridines, pyridothienopyrimidines and pyridothienotriazines: new antiprotozoals active against Philasterides dicentrarchi

AU Quintela, Jose M.; Peinador, Carlos; Gonzalez, Liliana; Iglesias, Raul; Parama, Anabel; Alvarez, Francisca; Sanmartin, Manuel L.; Riguera, Ricardo

CS Facultad de Ciencias, Departamento de Quimica Fundamental e Industrial, Universidad de La Coruna, La Coruna, 15071, Spain

SO European Journal of Medicinal Chemistry (2003), 38(3), 265-275
CODEN: EJMCA5; ISSN: 0223-5234

PB Editions Scientifiques et Medicales Elsevier

DT Journal

LA English

OS CASREACT 139:197457

IT 583051-27-8P
RL: AGR (Agricultural use); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl-subtituted naphthyridines, pyridothienopyrimidines, and pyridothienotriazines as antiprotozoals active against Philasterides dicentrarchi)

RN 583051-27-8 CAPLUS
CN 1,8-Naphthyridine-3,6-dicarbonitrile,
2-ethoxy-4-phenyl-7-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



OSC.G 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Title compds. (I; X = H, alkyl, aralkyl, acetoxymethyl, pivaloyloxymethyl, heterocyclylalkyl, etc.; R1, R2 = H, alkyl, aralkyl, aminoalkyl, trifluoroalkyl, halo; R3 = H, alkyl, glycosyl, aralkyl, alkanoyl, aminoalkanoyl; R4 = H, alkyl, CF3, Ph, F, etc.), were prepared Thus, diacetoxy-[(S)-8,9-difluoro-5-methyl-6,7-dihydro-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxy]borane, 4-hydroxy-4-trifluoromethylpiperidine, and Et3N were heated in Me2SO at 120° for 20 h to give 80% (S)-9-fluoro-6,7-dihydro-8-(4-hydroxy-4- trifluoromethylpiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine- 2-carboxylic acid. Tested I showed min. inhibitory concns. of 0.1-0.8 μg/mL against S. pneumoniae.
AN 2001:833316 CAPLUS Full-text
DN 135:371757
TI Preparation of chiral 8-piperidinobenzo[i,j]quinolizines as antibacterials.
IN De Souza, Noel John; Patel, Mahesh Vitalbhai; Agarwal, Shiv Kumar; Gupte, Shrikant Vinayak; Upadhyay, Dilip Jatashankar; Bhawsar, Satish Baliram; Jafri, Mohammad Alam; Khorakiwala, Habil F.
PA India
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001085728	A2	20011115	WO 2001-IN100	20010508

```
WO 2001085728        A3    20020912
    W:  AL, AM, AU, AZ, BB, BG, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB,
        HR, HU, ID, IL, IN, KE, KP, TM, TZ, UA, VN, YU, ZA, RU, TJ
    RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, DK, FI,
        FR, GB, GR, IT, LU, BJ, CG, GA, MR, SN, TD, TG
                                      US 2000-566875      A  20000508
                                      WO 2000-IN54        W  20000508
WO 2000068229        A2    20001116   WO 2000-IN54           20000508
WO 2000068229        A3    20010322
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
        CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
        ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
        LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
        SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
    RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
        DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
        CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                      WO 1999-IN16        A  19990507
                                      US 1999-170676P     P  19991214
US 20030207908       A1    20031106   US 2000-566875         20000508
US 7247642           B2    20070724
                                      WO 1999-IN16        A  19990507
                                      US 1999-170676P     P  19991214
CA 2417799           A1    20020207   CA 2001-2417799        20010731
                                      US 2000-222201P     P  20000801
                                      US 2000-640947      A  20000817
                                      WO 2000-IN111       A  20001122
                                      US 2001-286291P     P  20010425
                                      US 2001-850669      A  20010507
                                      WO 2001-IN100       A  20010508
                                      WO 2001-IN139       W  20010731
WO 2002009758        A2    20020207   WO 2001-IN139          20010731
WO 2002009758        A3    20021227
    W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
        CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
        GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
        LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
        RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
        UZ, VN, YU, ZA, ZW
    RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
        DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
        BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                      US 2000-222201P     P  20000801
                                      US 2000-640947      A  20000817
                                      WO 2000-IN111       A  20001122
                                      US 2001-286291P     P  20010425
                                      US 2001-850669      A  20010507
                                      WO 2001-IN100       A  20010508
AU 2001080091        A     20020213   AU 2001-80091          20010731
                                      US 2000-222201P     P  20000801
                                      US 2000-640947      A  20000817
                                      WO 2000-IN111       A  20001122
                                      US 2001-286291P     P  20010425
                                      US 2001-850669      A  20010507
                                      WO 2001-IN100       W  20010508
                                      WO 2001-IN139       W  20010731
EP 1305048           A2    20030502   EP 2001-958373         20010731
    R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
        IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                      US 2000-222201P     P  20000801
```

				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
				WO 2001-IN139	W	20010731
	IN 2002MN01549	A	20070601	IN 2002-MN1549		20021101
				US 2000-566875	A	20000508
				WO 2001-IN100	W	20010508
	IN 2003MN00128	A	20060616	IN 2003-MN128		20030127
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
				WO 2001-IN139	W	20010731
	US 20080044466	A1	20080221	US 2007-804770		20070521
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A3	20000508
	US 20080108646	A1	20080508	US 2007-880645		20070723
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A1	20000508

PATENT FAMILY INFORMATION:

FAN 2000:814485

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2000068229	A2	20001116	WO 2000-IN54		20000508
	WO 2000068229	A3	20010322			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
	CA 2373291	A1	20001116	CA 2000-2373291		20000508
	CA 2373291	C	20070206			
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				WO 2000-IN54	W	20000508
	AU 2000054256	A	20001121	AU 2000-54256		20000508
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				WO 2000-IN54	W	20000508
	EP 1175217	A2	20020130	EP 2000-939047		20000508
	EP 1175217	B1	20081203			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY					
				WO 1999-IN16	W	19990507
				US 1999-170676P	P	19991214
				WO 2000-IN54	W	20000508
	AT 415969	T	20081215	AT 2000-939047		20000508
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214

	EP 2030620	A1	20090304	EP 2008-11257		20000508
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				EP 2000-939047	A3	20000508
	WO 2001085728	A2	20011115	WO 2001-IN100		20010508
	WO 2001085728	A3	20020912			
	W: AL, AM, AU, AZ, BB, BG, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, HR, HU, ID, IL, IN, KE, KP, TM, TZ, UA, VN, YU, ZA, RU, TJ					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, IT, LU, BJ, CG, GA, MR, SN, TD, TG					
				US 2000-566875	A	20000508
				WO 2000-IN54	W	20000508
	IN 2001MN01369	A	20071207	IN 2001-MN1369		20011106
				WO 1999-IN16	A	19990507
				WO 2000-IN54	W	20000508
	US 20080044466	A1	20080221	US 2007-804770		20070521
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A3	20000508
	US 20080108646	A1	20080508	US 2007-880645		20070723
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A1	20000508
FAN	2001:833024					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	---	---	---	---	---	---
PI	WO 2001085095	A2	20011115	WO 2001-IN97		20010503
	WO 2001085095	A3	20021003			
	W: AE, AG, AT, AU, BG, BR, BZ, CA, CN, DE, DK, GH, HU, ID, IN, IS, KR, LS, LT, LV, MA, MN, PL, PT, RO, RU, TM, TT, TZ, UZ, YU, ZA, BY, MD, TJ					
	RW: GH, GM, LS, MW, SD, SL, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, TR, BF, CF, CI, MR, NE, SN, TD, TG					
				US 2000-566875	A	20000508
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-802793	A	20010309
	US 20030207908	A1	20031106	US 2000-566875		20000508
	US 7247642	B2	20070724			
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
	US 6750224	B1	20040615	US 2000-640947		20000817
				US 1999-170676P	P	19991214
				US 2000-566875	A2	20000508
	US 20020061908	A1	20020523	US 2001-802793		20010309
	US 6514986	B2	20030204			
				WO 2000-IN111	A	20001122
	CA 2403264	A1	20011115	CA 2001-2403264		20010503
				US 2000-566875	A	20000508
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-802793	A	20010309
				WO 2001-IN97	W	20010503
	AU 2001078666	A	20011120	AU 2001-78666		20010503
				US 2000-566875	A	20000508
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-802793	A	20010309

				WO 2001-IN97	W	20010503
	EP 1311506	A2	20030521	EP 2001-956751		20010503
	EP 1311506	B1	20071114			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2000-566875	A	20000508
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-802793	A	20010309
				WO 2001-IN97	W	20010503
	US 20080044466	A1	20080221	US 2007-804770		20070521
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A3	20000508
	US 20080108646	A1	20080508	US 2007-880645		20070723
				WO 1999-IN16	A	19990507
				US 1999-170676P	P	19991214
				US 2000-566875	A1	20000508

FAN 2002:107157

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002009758	A2	20020207	WO 2001-IN139		20010731
	WO 2002009758	A3	20021227			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
	US 6750224	B1	20040615	US 2000-640947		20000817
				US 1999-170676P	P	19991214
				US 2000-566875	A2	20000508
	US 20020165227	A1	20021107	US 2001-850669		20010507
	US 6608078	B2	20030819			
				US 2000-202459P	P	20000508
	WO 2001085728	A2	20011115	WO 2001-IN100		20010508
	WO 2001085728	A3	20020912			
	W: AL, AM, AU, AZ, BB, BG, CA, CH, CU, CZ, DE, DK, EE, ES, FI, GB, HR, HU, ID, IL, IN, KE, KP, TM, TZ, UA, VN, YU, ZA, RU, TJ					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, AT, BE, CH, CY, DE, DK, FI, FR, GB, GR, IT, LU, BJ, CG, GA, MR, SN, TD, TG					
				US 2000-566875	A	20000508
				WO 2000-IN54	W	20000508
	CA 2417799	A1	20020207	CA 2001-2417799		20010731
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
				WO 2001-IN139	W	20010731

	AU 2001080091	A	20020213	AU 2001-80091		20010731
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	W	20010508
				WO 2001-IN139	W	20010731
	US 20020177559	A1	20021128	US 2001-919347		20010731
	US 7098219	B2	20060829			
				US 2000-222201P	P	20000801
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
	EP 1305048	A2	20030502	EP 2001-958373		20010731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
				WO 2001-IN139	W	20010731
	IN 2003MN00128	A	20060616	IN 2003-MN128		20030127
				US 2000-222201P	P	20000801
				US 2000-640947	A	20000817
				WO 2000-IN111	A	20001122
				US 2001-286291P	P	20010425
				US 2001-850669	A	20010507
				WO 2001-IN100	A	20010508
				WO 2001-IN139	W	20010731

FAN 2002:832782

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2002085886	A2	20021031	WO 2002-IN111		20020424
	WO 2002085886	A3	20030522			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341365P	P	20011213
	US 20020177559	A1	20021128	US 2001-919347		20010731
	US 7098219	B2	20060829			
				US 2000-222201P	P	20000801
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
	CA 2445888	A1	20021031	CA 2002-2445888		20020424
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341365P	P	20011213
				WO 2002-IN111	W	20020424
	AU 2002302963	A1	20021105	AU 2002-302963		20020424

				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341365P	P	20011213
				WO 2002-IN111	W	20020424
EP 1392677		A2	20040303	EP 2002-730678		20020424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341165P	P	20011213
				WO 2002-IN111	W	20020424
JP 2005504729		T	20050217	JP 2002-583413		20020424
JP 4342797		B2	20091014			
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341165P	P	20011213
				WO 2002-IN111	W	20020424
CA 2468190		A1	20030619	CA 2002-2468190		20021212
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
WO 2003050107		A1	20030619	WO 2002-IN232		20021212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
AU 2002361493		A1	20030623	AU 2002-361493		20021212
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
US 20030216568		A1	20031120	US 2002-318367		20021212
US 6878713		B2	20050412			
				US 2001-286291P	P	20010425
				US 2001-341165P	P	20011213
				US 2002-128996	A2	20020423
				WO 2002-IN111	A	20020424
EP 1453824		A1	20040908	EP 2002-796957		20021212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK						
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
JP 2005511743		T	20050428	JP 2003-551131		20021212
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
IN 2003MN00972		A	20050429	IN 2003-MN972		20031016

				WO 2002-IN111	W	20020424
	US 20050065164	A1	20050324	US 2004-945504		20040920
	US 7393957	B2	20080701			
				US 2001-286291P	P	20010425
				US 2001-341165P	P	20011213
				US 2002-128996	A2	20020423
				WO 2002-IN111	A	20020424
				US 2002-318367	A3	20021212
	US 20080214608	A1	20080904	US 2008-150075		20080424
	US 7626032	B2	20091201			
				US 2001-286291P	P	20010425
				US 2001-341165P	P	20011213
				US 2002-128996	A2	20020423
				WO 2002-IN111	A	20020424
				US 2002-318367	A3	20021212
				US 2004-945504	A3	20040920

FAN 2003:472505

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2003050107	A1	20030619	WO 2002-IN232		20021212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
	US 20030096812	A1	20030522	US 2002-128996		20020423
	US 6964966	B2	20051115			
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341165P	P	20011213
	WO 2002085886	A2	20021031	WO 2002-IN111		20020424
	WO 2002085886	A3	20030522			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341365P	P	20011213
	CA 2468190	A1	20030619	CA 2002-2468190		20021212
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
	AU 2002361493	A1	20030623	AU 2002-361493		20021212
				US 2001-341165P	P	20011213

				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
	EP 1453824	A1	20040908	EP 2002-796957		20021212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
	JP 2005511743	T	20050428	JP 2003-551131		20021212
				US 2001-341165P	P	20011213
				US 2002-128996	A	20020423
				WO 2002-IN111	A	20020424
				WO 2002-IN232	W	20021212
	IN 2004MN00274	A	20050429	IN 2004-MN274		20040512
				WO 2002-IN232	W	20021212

FAN 2003:912885

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 20030216568	A1	20031120	US 2002-318367		20021212
	US 6878713	B2	20050412			
				US 2001-286291P	P	20010425
				US 2001-341165P	P	20011213
				US 2002-128996	A2	20020423
				WO 2002-IN111	A	20020424
	US 20020177559	A1	20021128	US 2001-919347		20010731
	US 7098219	B2	20060829			
				US 2000-222201P	P	20000801
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
	US 20030096812	A1	20030522	US 2002-128996		20020423
	US 6964966	B2	20051115			
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341165P	P	20011213
	WO 2002085886	A2	20021031	WO 2002-IN111		20020424
	WO 2002085886	A3	20030522			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2001-286291P	P	20010425
				US 2001-287104P	P	20010427
				US 2001-341365P	P	20011213
	US 20050065164	A1	20050324	US 2004-945504		20040920
	US 7393957	B2	20080701			
				US 2001-286291P	P	20010425
				US 2001-341165P	P	20011213
				US 2002-128996	A2	20020423
				WO 2002-IN111	A	20020424
				US 2002-318367	A3	20021212
	US 20080214608	A1	20080904	US 2008-150075		20080424
	US 7626032	B2	20091201			

				US 2001-286291P	P 20010425
				US 2001-341165P	P 20011213
				US 2002-128996	A2 20020423
				WO 2002-IN111	A 20020424
				US 2002-318367	A3 20021212
				US 2004-945504	A3 20040920

FAN 2004:485161

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6750224	B1	20040615	US 2000-640947	20000817
				US 1999-170676P	P 19991214
				US 2000-566875	A2 20000508
	US 20030207908	A1	20031106	US 2000-566875	20000508
	US 7247642	B2	20070724		
				WO 1999-IN16	A 19990507
				US 1999-170676P	P 19991214
	EP 2030620	A1	20090304	EP 2008-11257	20000508
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				WO 1999-IN16	A 19990507
				US 1999-170676P	P 19991214
				EP 2000-939047	A3 20000508
	CA 2403264	A1	20011115	CA 2001-2403264	20010503
				US 2000-566875	A 20000508
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-802793	A 20010309
				WO 2001-IN97	W 20010503
	WO 2001085095	A2	20011115	WO 2001-IN97	20010503
	WO 2001085095	A3	20021003		
	W: AE, AG, AT, AU, BG, BR, BZ, CA, CN, DE, DK, GH, HU, ID, IN, IS, KR, LS, LT, LV, MA, MN, PL, PT, RO, RU, TM, TT, TZ, UZ, YU, ZA, BY, MD, TJ				
	RW: GH, GM, LS, MW, SD, SL, TZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, TR, BF, CF, CI, MR, NE, SN, TD, TG				
				US 2000-566875	A 20000508
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-802793	A 20010309
	AU 2001078666	A	20011120	AU 2001-78666	20010503
				US 2000-566875	A 20000508
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-802793	A 20010309
				WO 2001-IN97	W 20010503
	EP 1311506	A2	20030521	EP 2001-956751	20010503
	EP 1311506	B1	20071114		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-566875	A 20000508
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-802793	A 20010309
				WO 2001-IN97	W 20010503
	AT 378335	T	20071115	AT 2001-956751	20010503
				US 2000-566875	A 20000508
				US 2000-640947	A 20000817
				WO 2000-IN111	W 20001122
				US 2001-802793	A 20010309
	CA 2417799	A1	20020207	CA 2001-2417799	20010731

				US 2000-222201P	P 20000801
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-286291P	P 20010425
				US 2001-850669	A 20010507
				WO 2001-IN100	A 20010508
				WO 2001-IN139	W 20010731
WO 2002009758		A2	20020207	WO 2001-IN139	20010731
WO 2002009758		A3	20021227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				US 2000-222201P	P 20000801
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-286291P	P 20010425
				US 2001-850669	A 20010507
				WO 2001-IN100	A 20010508
AU 2001080091		A	20020213	AU 2001-80091	20010731
				US 2000-222201P	P 20000801
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-286291P	P 20010425
				US 2001-850669	A 20010507
				WO 2001-IN100	W 20010508
				WO 2001-IN139	W 20010731
EP 1305048		A2	20030502	EP 2001-958373	20010731
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 2000-222201P	P 20000801
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-286291P	P 20010425
				US 2001-850669	A 20010507
				WO 2001-IN100	A 20010508
				WO 2001-IN139	W 20010731
US 20030144517		A1	20030731	US 2002-303692	20021122
US 6753333		B2	20040622		
				US 1999-170676P	P 19991214
				US 2000-566875	A2 20000508
				US 2000-640947	A1 20000817
				WO 2000-IN111	A 20001122
				US 2001-802793	A3 20010309
IN 2003MN00128		A	20060616	IN 2003-MN128	20030127
				US 2000-222201P	P 20000801
				US 2000-640947	A 20000817
				WO 2000-IN111	A 20001122
				US 2001-286291P	P 20010425
				US 2001-850669	A 20010507
				WO 2001-IN100	A 20010508
				WO 2001-IN139	W 20010731
US 20080044466		A1	20080221	US 2007-804770	20070521
				WO 1999-IN16	A 19990507
				US 1999-170676P	P 19991214

				US 2000-566875	A3 20000508
US 20080108646	A1	20080508	US 2007-880645		20070723
			WO 1999-IN16	A	19990507
			US 1999-170676P	P	19991214
			US 2000-566875	A1	20000508

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 135:371757

IT 373603-57-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of chiral piperidinobenzoquinolizines as antibacterials)

RN 373603-57-7 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-4-phenyl-1-piperidinyl)-5-methyl-1-oxo-, (5S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

GI



I

AB Title compds. [I; R = H; 1 of R1-R3 = NR5R6, 1 = halo, and the other = H, halo, NR5R6; R4 = (fluoro)alkyl, carboxyalkyl, cycloalkyl, (di)fluorophenyl, alkoxy, alkylamino; NR5R6 = heterocyclyl] were prepared as bactericides (no data). Thus, 2-amino-4-chloro-3,5-difluorobenzaldehyde (preparation given) was cyclocondensed with O2NCH2CH:NOH and the reduced product condensed with EtOCH:C(CO2Et)2 to give, after cyclization and N-methylation, I (R2 = Cl, R3 = F, R4 = Me)(II; R = Et, R1 = F) which was aminated by 1-(3-fluoro-4-

methylphenyl)piperazine to give, after saponification, II [R = H, R1 = 4-(3-fluoro-4-methylphenyl)-1-piperazinyl].

AN 2001:31500 CAPLUS Full-text

DN 134:100855

TI Preparation of 1-oxobenzo[f][1,7]naphthyridine-2-carboxylic acids as bactericides

IN Desconclois, Jean-Francois; Genevois-Borella, Arielle; Girard, Philippe; Kryvenko, Michel; Lavergne, Marc Pierre; Malleron, Jean-Luc; Picaut, Guy; Tabart, Michel; Wentzler, Sylvie

PA Aventis Pharma S.A., Fr.

SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI WO 2001002396	A1	20010111	WO 2000-FR1819		20000629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
FR 2795729	A1	20010105	FR 1999-8376		19990630
EP 1189903	A1	20020327	EP 2000-949571		20000629
EP 1189903	B1	20030528			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
			WO 2000-FR1819	W	20000629
JP 2003503495	T	20030128	JP 2001-507833		20000629
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
			WO 2000-FR1819	W	20000629
AT 241624	T	20030615	AT 2000-949571		20000629
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
			WO 2000-FR1819	W	20000629
PT 1189903	E	20031031	PT 2000-949571		20000629
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
ES 2200899	T3	20040316	ES 2000-949571		20000629
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
US 20020137741	A1	20020926	US 2001-29950		20011231
US 6566362	B2	20030520			
			FR 1999-8376	A	19990630
			US 1999-148212P	P	19990812
			WO 2000-FR1819	A1	20000629

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 134:100855

IT 318683-88-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-oxobenzo[f][1,7]naphthyridine-2-carboxylic acids as bactericides)

RN 318683-88-4 CAPLUS

CN Benzo[f][1,7]naphthyridine-2-carboxylic acid, 7-fluoro-1,4-dihydro-8-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-4-methyl-1-oxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

GI



I

AB Cytokine formation inhibitors contain (I; R1 = C1-6 alkyl; R2, R3, R4, R6 = H, etc.; R5 = halogen, etc.; X = H, etc.; A = N, etc.; m = 2 or 3; Y = Oh; Z = C, etc.) and their salts for treatment of cytokines-related diseases. The cytokines include IL-1 to IL-15, TNF-α, M-CAF, RANTES, MIP-1, SCF, GM-CSF, G-CSF, M-CSF, erythropoietin, thrombopoietin, interferon, NGF, TGF-β, PDGF, EGF, and LIF.

AN 1999:380682 CAPLUS Full-text

DN 131:68133

TI Cytokine formation inhibitors for treatment of cytokines-related diseases

IN Baba, Masanori; Ikeuchi, Kiyoshi; Kimura, Yoichi

PA Daiichi Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI JP 11158071 A 19990615 JP 1997-331575 19971202
JP 3739916 B2 20060125
JP 1997-331575 19971202

IT 228548-93-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cytokine formation inhibitors for treatment of cytokines-related diseases)

RN 228548-93-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 8-(difluoromethoxy)-6-fluoro-1,4-dihydro-4-oxo-7-(4-phenyl-1-piperidinyl)-1-[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- (CA INDEX NAME)



L7 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

AB Seven analogs of tricyclic rufloxacin were prepd. and their MIC were evaluated against 13 kinds of bacteria. One of the compds. had better antibacterial activity than rufloxacin in vitro.

AN 1999:74954 CAPLUS Full-text

DN 130:332303

TI Synthesis and antibacterial activity of tricyclic fluoroquinolones

AU Xiong, Wennan; Wang, Erhua; Tang, Zhiyue

CS Medicinal and Chemical Engineering Institute, China Pharmaceutical University, Nanjing, 210009, Peop. Rep. China

SO Zhongguo Yaowu Huaxue Zazhi (1998), 8(3), 174-177
CODEN: ZYHZEF; ISSN: 1005-0108

PB Zhongguo Yaowu Huaxue Zazhi Bianjibu

DT Journal

LA Chinese

IT 224313-58-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antibacterial activity of tricyclic fluoroquinolones)

RN 224313-58-0 CAPLUS

CN 7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 10-[4-(ethoxycarbonyl)-4-phenyl-1-piperidinyl]-9-fluoro-2,3-dihydro-7-oxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L7 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



AB The title compds. [I; R = H, Br, Cl, F, NO2; R1 = H, Cl, F, R2R3N; R2, R3 = alkyl, hydroxyalkyl; R2R3N = (un)substituted heterocyclyl] (89 compds.) were prepared Thus, CH2(CO2Et)2 underwent Grignard benzoylation with 2,4,5-Cl2FC6H2COCl to give 2,4,5-Cl2FC6H2COCH(CO2Et)2. This was decarboxylated and condensed with HC(OEt)3 to give 2,4,5-Cl2FC6H2COC(:CHOEt)CO2Et which was treated with cyclopropylamine and cyclized to give I (R = F, R1 = Cl). This was treated with piperazine to give II.HCl. On rice plants 0.025% II.HCl gave 80% protection against damage by Xanthomonas oryzae.

AN 1984:611165 CAPLUS Full-text
DN 101:211165
OREF 101:31999a,32002a
TI Microbicidal composition based on quinolonecarboxylic acid
IN Grohe, Klaus; Petersen, Uwe; Kuck, Karl Heinz
PA Bayer A.-G. , Fed. Rep. Ger.
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 3248507	A1	19840705	DE 1982-3248507		19821229
	US 4563459	A	19860107	US 1983-561441		19831214
				DE 1982-3248507	A	19821229
	EP 113091	A1	19840711	EP 1983-112720		19831217
	EP 113091	B1	19860730			
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL					
				DE 1982-3248507	A	19821229
	AT 21011	T	19860815	AT 1983-112720		19831217
				DE 1982-3248507	A	19821229
				EP 1983-112720	A	19831217
	AU 8322863	A	19840705	AU 1983-22863		19831223
	AU 563747	B2	19870723			
				DE 1982-3248507	A	19821229
	CA 1232198	A1	19880202	CA 1983-444242		19831223

				DE 1982-3248507	A	19821229
IL 70540	A	19870731	IL 1983-70540			19831226
			DE 1982-3248507	A		19821229
BR 8307166	A	19840807	BR 1983-7166			19831227
			DE 1982-3248507	A		19821229
DK 8306038	A	19840630	DK 1983-6038			19831228
			DE 1982-3248507	A		19821229
ZA 8309647	A	19840829	ZA 1983-9647			19831228
			DE 1982-3248507	A		19821229
HU 32709	A2	19840928	HU 1983-4498			19831228
HU 194482	B	19880229				
			DE 1982-3248507	A		19821229
JP 59130802	A	19840727	JP 1983-252506			19831229
			DE 1982-3248507	A		19821229

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 101:211165; MARPAT 101:211165

IT 93106-79-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 93106-79-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

L7 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN

GI



I

AB Benzoheterocyclic compds. I (R1 = H or alkyl; R2 = H or halogen; R3 = 1-pyrrolidinyl, 1,2,5,6-tetrahydro-1-pyridyl, 1-piperazinyl, etc., n = 1 or 2) are antimicrobial agents. Thus, 9-fluoro-8-(4-hydroxy-1-piperidyl)-5-methyl-6,7-dihydro-1-oxo-1H,5H- benzo[ij] quinalizine-2-carboxylic acid (I; R1 = Me, R2 = 9-F, R3 = 8-(4-hydroxypiperidino), n = 2)(II) [81962-84-7] was prepared by treating 9-fluoro-8-(bromo-5-methyl-6,7-dihydro-1-oxo-1H,5H-benzo[ij]quinalizine-2- carboxylic acid [77483-92-2] with 4-hydroxypiperidine [5382-16-1]. An ointment was prepared by mixing II Na salt [86826-12-2] 2, lanolin 5, beeswax 5, and white vaseline 88 g. Forty-two I were synthesized

and their activities against 41 species of bacteria such as Escherichia coli, Bacillus cereus, Staphylococcus aureus, etc. were shown.

AN 1983:493740 CAPLUS Full-text
DN 99:93740
OREF 99:14385a,14388a
TI Benzoquinalizines and pyrroloquinolines antimicrobial agents
PA Otsuka Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 35 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58090511	A	19830530	JP 1981-189806	19811125
JP 01041127	B	19890904		
			JP 1981-189806	19811125

IT 81962-88-1P
RL: THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)
RN 81962-88-1 CAPLUS
CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-5-methyl-1-oxo-8-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L7 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Quinolinones I [n = 1, 2; R = H, alkyl; R1 = H, halogen; R2 = (un)substituted pyrrolidino, tetrahydropyrido, piperidino, morpholino, piperazino] were prepared Thus 1.05 g I [n = 2, R = Me, R1 = 9-F, R2 = 8-(4-

hydroxypiperidino), II] was obtained by reaction of 7.5 g I (n = 2, R = Me, R1 = 9-F, R2 = 8-Br) with 9.5 g 4-piperidinol. I had a min. inhibitory concentration against Escherichia coli NIHJ JC-2 of 0.39 μg/mL.

AN 1982:406177 CAPLUS Full-text
DN 97:6177
OREF 97:1191a,1194a
TI Benzoheterocyclic compounds used as antimicrobial medicines
IN Ishikawa, Hiroshi; Nakagawa, Kazuyuki; Uno, Testuyuki; Kano, Masanobu
PA Otsuka Pharmaceutical Co., Ltd. , Japan
SO Belg., 83 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	BE 891046	A1	19820301	BE 1981-206483		19811109
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	JP 57081486	A	19820521	JP 1980-158652		19801110
	JP 01007996	B	19890210			
	JP 57176987	A	19821030	JP 1981-63170		19810424
	JP 02022074	B	19900517			
	NO 8103726	A	19820511	NO 1981-3726		19811104
	NO 156828	B	19870824			
	NO 156828	C	19871202			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	AT 8104748	A	19920215	AT 1981-4748		19811105
	AT 395150	B	19920925			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	DK 8104952	A	19820511	DK 1981-4952		19811109
	DK 160940	B	19910506			
	DK 160940	C	19911021			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	FI 8103526	A	19820511	FI 1981-3526		19811109
	FI 71141	B	19860814			
	FI 71141	C	19861124			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	SE 8106642	A	19820614	SE 1981-6642		19811109
	SE 448542	B	19870302			
	SE 448542	C	19870611			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	DE 3144455	A1	19820624	DE 1981-3144455		19811109
	DE 3144455	C2	19901004			
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	ZA 8107733	A	19821027	ZA 1981-7733		19811109
				JP 1980-158652	A	19801110
	SU 1366055	A3	19880107	SU 1981-3354800		19811109
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
	DE 3153221	C2	19910704	DE 1981-3153221		19811109
				JP 1981-63170	A	19810424
	FR 2493849	A1	19820514	FR 1981-21100		19811110
	FR 2493849	B1	19841228			

				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
GB 2086905	A	19820519		GB 1981-33890		19811110
GB 2086905	B	19841205				
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
NL 8105075	A	19820601		NL 1981-5075		19811110
NL 193457	B	19990701				
NL 193457	C	19991102				
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
AU 8177335	A	19820805		AU 1981-77335		19811110
AU 546358	B2	19850829				
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
US 4399134	A	19830816		US 1981-320027		19811110
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
CA 1179341	A1	19841211		CA 1981-389769		19811110
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
CH 648845	A5	19850415		CH 1981-7200		19811110
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
SU 1277896	A3	19861215		SU 1982-3527501		19821227
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
US 4552879	A	19851112		US 1983-497914		19830525
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
				US 1981-320027	A3	19811110
AT 8902887	A	19910315		AT 1989-2887		19891220
AT 393383	B	19911010				
				JP 1980-158652	A	19801110
				JP 1981-63170	A	19810424
				AT 1981-4748	A	19811105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 97:6177; MARPAT 97:6177

IT 81962-88-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 81962-88-1 CAPLUS

CN 1H,5H-Benzo[ij]quinolizine-2-carboxylic acid,
9-fluoro-6,7-dihydro-5-methyl-1-oxo-8-[4-(phenylmethyl)-1-piperidinyl]-
(CA INDEX NAME)



OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (28 CITINGS)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10583419.str



chain nodes :
8
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
chain bonds :
6-8 8-9 12-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 23-24
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 6-8 8-9 9-10 9-14 10-11 11-12 12-13 12-15 13-
14 15-16 15-20 16-17 17-18 18-19 18-21 19-20 19-24 21-22 22-23 23-24
isolated ring systems :
containing 1 : 9 : 15 :

G1:C,N

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jan 4, 2010 (20100104/UP).

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l8
SAMPLE SEARCH INITIATED 13:39:04 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1095 TO ITERATE

100.0% PROCESSED   1095 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 19915 TO   23885
PROJECTED ANSWERS: 1 TO   80

L9   1 SEA SSS SAM L8

=> s l8 ful
FULL SEARCH INITIATED 13:39:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   21544 TO ITERATE

100.0% PROCESSED   21544 ITERATIONS   26 ANSWERS
SEARCH TIME: 00.00.01

L10   26 SEA SSS FUL L8

=> file caplus
Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l10
L11   10 L10

=> d abs bib hitstr 1-10

L11 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Fifty one quinoline-3-carboxylic acids I (R1 = c-Pr, t-Bu, 2,4-F2C6H3; R2R3N = 17 secondary amines) were synthesized from 1,3-dichloro-2-methylbenzene and evaluated for in-vitro antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB), and Mycobacterium smegmatis (MC2). Among the synthesized compds., I (R1 = c-Pr, R2R3N = 1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl) was found to be the most active compound in vitro with a MIC value of 0.39 μM against MTB. Against MDR-TB, compound I (R1 = c-Pr, R2R3N = 2-carboxy-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-7-yl) was found to be the most active with a MIC value of 0.09 μM. Generally, quinoline-3-carboxylic acids I (R1 = c-Pr) were most active and most were tested for their cytotoxicity in a mammalian Vero cell line.

AN 2009:254822 CAPLUS Full-text

DN 150:472531

TI Synthesis and in-vitro antimycobacterial evaluation of 1-(cyclopropyl/2,4-difluorophenyl/tert-butyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo-7-(substituted secondary amino)quinoline-3-carboxylic acids

AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Chandraseakaran, Yogesh; Yogeeswari, Perumal; Sriram, Dharmarajan

CS Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, India

SO Archiv der Pharmazie (Weinheim, Germany) (2009), 342(2), 100-112
CODEN: ARPMAS; ISSN: 0365-6233

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

OS CASREACT 150:472531

IT 1146300-42-6P 1146300-59-5P 1146300-76-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of (amino)(oxo)quinolinecarboxylic acids and their antimycobacterial structure-activity relationships)

RN 1146300-42-6 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methyl-6-nitro-4-oxo- (CA INDEX NAME)



RN 1146300-59-5 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(2,4-difluorophenyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo- (CA INDEX NAME)



RN 1146300-76-6 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-8-methyl-6-nitro-4-oxo- (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Various 1-(substituted)-1,4-dihydro-6-nitro-4-oxo-7-(sub-secondary amino)-quinoline-3-carboxylic acids were synthesized from 2,4-dichlorobenzoic acid by six step synthesis. The compds. were evaluated for antimycobacterial in vitro and in vivo against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the 48 synthesized compds., compound I was found to be the most active compound in vitro with MIC of 0.08 and 0.16 μM against MTB and MDR-TB, resp. In the in vivo animal model, compound I decreased the bacterial load in lung and spleen tissues with 2.78 and 4.15-log 10 protections, resp., at the dose of 50 mg/kg body weight
AN 2009:5914 CAPLUS Full-text
DN 150:259917

TI Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids

AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Yogeeswari, Perumal; Sriram, Dharmarajan; China, Arnab; Nagaraja, Valakunja

CS Medicinal Chemistry Research Laboratory, Pharmacy Group, Birla Institute of Technology and Science, Pilani, 333031, India

SO European Journal of Medicinal Chemistry (2009), 44(1), 345-358
CODEN: EJMCA5; ISSN: 0223-5234

PB Elsevier Masson SAS

DT Journal

LA English

OS CASREACT 150:259917

IT 1119087-07-8P 1119087-58-9P 1119088-09-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of nitroquinolinolonecarboxylic acids via nitration of dichlorobenzoic acid followed by alkylation, cyclization with amines and amination with secondary amines, and their antimycobacterial activity)

RN 1119087-07-8 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RN 1119087-58-9 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RN 1119088-09-3 CAPLUS

CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN

AB On the basis of our recent findings that 6-aminoquinolones inhibit the HIV Tat-mediated transactivation, we have designed a broad series of derivs. identifying novel potent agents such as the 6-desfluoroquinolones 24 (HM12) and 27 (HM13), which showed pronounced anti-HIV activity in acutely, chronically, and latently HIV-1 infected cell cultures. We demonstrate here that highly potent mols. can be obtained by optimizing the substituent in the various positions of the quinolone nucleus.

AN 2008:1015905 CAPLUS Full-text

DN 149:346718

TI Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones

AU Tabarrini, Oriana; Massari, Serena; Daelemans, Dirk; Stevens, Miguel; Manfroni, Giuseppe; Sabatini, Stefano; Balzarini, Jan; Cecchetti, Violetta; Pannecouque, Christophe; Fravolini, Arnaldo

CS Dipartimento di Chimica e Tecnologia del Farmaco, Universita di Perugia, Perugia, 06123, Italy

SO Journal of Medicinal Chemistry (2008), 51(17), 5454-5458
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 149:346718

IT 1056878-77-3P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and SAR of anti-HIV 6-desfluoroquinolones)

RN 1056878-77-3 CAPLUS

CN 3-Quinolinecarboxylic acid, 6-amino-1,4-dihydro-1-methyl-4-oxo-7-[4-(2-pyridinyl)-1-piperidinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 1056879-21-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and SAR of anti-HIV 6-desfluoroquinolones)
RN 1056879-21-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 1,4-dihydro-1-methyl-6-nitro-4-oxo-7-[4-(2-pyridinyl)-1-piperidinyl]-, ethyl ester (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
AB Thirty-four newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids were synthesized from 1,2,3,4-tetrafluoro benzene and evaluated for in vitro and in vivo antimycobacterial activities against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase. Among the synthesized compds., 7-(1-(4-methoxybenzyl)-3,4,5,6,7,8-hexahydroisoquinolin-2(1H)-yl)- 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxoquinoline-3- carboxylic acid (13n) was found to be the most active compound in vitro with MIC of 0.16 and 0.33 μM against MTB and MDR-TB, resp. In the in vivo animal model 13n decreased the bacterial load in lung and spleen tissues with 2.54 and 2.92 - log10 protections, resp., at the dose of 50 mg/kg body weight Compound 13n also inhibited the supercoiling activity of mycobacterial DNA gyrase with IC50 of 30.0 μg/mL.
AN 2008:339599 CAPLUS Full-text
DN 148:444657
TI Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids
AU Senthilkumar, Palaniappan; Dinakaran, Murugesan; Banerjee, Debjani; Devakaram, Ruth Vandana; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja; Sriram, Dharmarajan
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Bioorganic & Medicinal Chemistry (2008), 16(5), 2558-2569
CODEN: BMECEP; ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:444657
IT 1018937-82-0P 1018937-85-3P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids)
RN 1018937-82-0 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo- (CA INDEX NAME)



RN 1018937-85-3 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-5-nitro-4-oxo- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
AB Fifty-one 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acids were synthesized and evaluated for antimycobacterial in vitro and in vivo against Mycobacterium tuberculosis H37Rv (MTB), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) and also tested for the ability to inhibit the supercoiling activity of DNA gyrase from M. smegmatis. Among the synthesized compds., 1-tert-butyl-1,4-dihydro-7-(4,4-dimethyloxazolidin-3-yl)-6-nitro-4-oxo-1,8- naphthyridine-3-carboxylic acid (10q) is the most active compound in vitro with an MIC of 0.1 μM against MTB and MDR-TB and was 3 and 455 times more potent than isoniazid against MTB and MDR-TB, resp. In the in vivo animal model 10q decreased the bacterial load in lung and spleen tissues with 2.39 and 3.89-log10protections, resp., at the dose of 50 mg/kg body weight
AN 2007:1215588 CAPLUS Full-text
DN 148:78912
TI Antimycobacterial Activities of Novel 1-(Cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic Acid
AU Sriram, Dharmarajan; Senthilkumar, Palaniappan; Dinakaran, Murugesan; Yogeeswari, Perumal; China, Arnab; Nagaraja, Valakunja
CS Medicinal Chemistry Research Laboratory, Pharmacy group, Birla Institute of Technology and Science, Pilani, 333031, India
SO Journal of Medicinal Chemistry (2007), 50(24), 6232-6239
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 148:78912

IT 960314-15-2P, 7-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo-1,8-naphthyridine-3-carboxylic Acid 960314-16-3P, 7-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1,4-dihydro-1-(4-fluorophenyl)-6-nitro-4-oxo-1,8-naphthyridine-3-carboxylic acid 960314-17-4P, 1-tert-Butyl-7-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1,4-dihydro-6-nitro-4-oxo-1,8-naphthyridine-3-carboxylic acid
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acids)

RN 960314-15-2 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-cyclopropyl-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RN 960314-16-3 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



RN 960314-17-4 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(1,1-dimethylethyl)-1,4-dihydro-6-nitro-4-oxo- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN

AB Substituted pyridines and pyrimidines and compns. contg. them are claimed for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotizing agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders. Example compound 4-(4-tert-butylphenyl)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6- yl)pyridin-2(1H)-one was prepared by reacting 4-(4-tert-butylphenyl)pyridin-2(1H)-one and 1-bromo-3,4-(ethylenedioxy)benzene. No biol. data is given in the patent.

AN 2007:701137 CAPLUS Full-text
DN 147:118146

TI Preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands for treatment of pain, inflammatory conditions, and other diseases

IN Chen, Ning; Nishimura, Nobuko; Norman, Mark H.; Ognyanov, Vassil I.; Ognyanov, Diana
PA Amgen, Inc., USA

SO U.S. Pat. Appl. Publ., 51 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070149513	A1	20070628	US 2006-644226	20061222
WO 2007076104	A1	20070705	WO 2006-US49208	20061222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2005-753994P P 20051223
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 147:118146
IT 942947-13-9P, 1-(Quinolin-7-yl)-4-[4-(trifluoromethyl)phenyl]piperidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted pyridines and pyrimidines as vanilloid receptor ligands for treatment of pain, inflammatory conditions, and other diseases)
RN 942947-13-9 CAPLUS
CN 2-Piperidinone, 1-(7-quinolinyl)-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



L11 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a prepn. of quinoline and [1,8]naphthyridine derivs. of formula I [wherein: A is (cyclo)alkylene, alk(en/yn)ylene, or heteroarylene, etc.; Q is N, C(OH), or heteroalkyl, etc.; X is N, CH, C(F), C(OH), or C(NH2), etc.; Y is N, CH, or C(OMe), etc.; Z and L are independently (CH2)1-3; R1 is H, halogen, or NH2, etc.; R2 is H, F, or Cl; R3 is H, (cyclo)alkyl, alk(en/yn)yl, or (hetero)aryl, etc.; R4 is a derivative of oxazole, furan, or isoxazole], useful as antimicrobial agents (no biol. data). The invention compds. are effective against a variety of multi-drug resistant bacteria. For instance, [1,8]naphthyridine derivative II was prepared via amination of 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4- oxo-[1,8]naphthyridine-3-carboxylic acid by piperidine derivative III with a yield of 64%.
AN 2005:570890 CAPLUS Full-text
DN 143:97344
TI A preparation of quinoline and [1,8]naphthyridine derivatives, useful as antibiotics
IN Hubschwerlen, Christian; Specklin, J. L.; Baeschlin, Daniel Kaspar; Sigwalt, Christine; Mueller, Stefan; Cappi, Michael
PA Morphochem A.-G., Germany
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005058888	A2	20050630	WO 2004-EP14500	20041220

```
     WO 2005058888        A3    20050818
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1557416           A1    20050727    EP 2004-1506          20040123
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AU 2004299278        A1    20050630    AU 2004-299278        20041220
     CA 2549675           A1    20050630    CA 2004-2549675       20041220
     EP 1709044           A2    20061011    EP 2004-804099        20041220
     EP 1709044           B1    20080716
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1898238           A     20070117    CN 2004-80038072      20041220
     BR 2004017193        A     20070306    BR 2004-17193         20041220
     JP 2007516263        T     20070621    JP 2006-544382        20041220
     ZA 2006004180        A     20071128    ZA 2006-4180          20041220
     AT 401326            T     20080815    AT 2004-804099        20041220
     PT 1709044           E     20081027    PT 2004-804099        20041220
     ES 2310299           T3    20090101    ES 2004-804099        20041220
     RU 2371443           C2    20091027    RU 2006-125510        20041220
     IN 2006MN00693       A     20070323    IN 2006-MN693         20060613
     MX 2006006769        A     20061219    MX 2006-6769          20060615
     KR 2007067003        A     20070627    KR 2006-714403        20060718
     HK 1090647           A1    20080905    HK 2006-112470        20061113
     US 20080027040       A1    20080131    US 2007-583419        20070928
PRAI US 2003-530822P      P     20031218
     EP 2004-1506         A     20040123
     WO 2004-EP14500      W     20041220
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   CASREACT 143:97344; MARPAT 143:97344
IT   856677-21-9P   856677-23-1P   856677-37-7P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of quinoline and [1,8]naphthyridine derivs. useful as
        antibiotics)
RN   856677-21-9  CAPLUS
CN   3-Quinolinecarboxylic acid, 7-[4-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-
     3-oxazolidinyl]-2-fluorophenyl]ethynyl]-4-hydroxy-1-piperidinyl]-1-
     cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-  (CA INDEX NAME)

Absolute stereochemistry.
```



RN 856677-23-1 CAPLUS
CN 1,8-Naphthyridine-3-carboxylic acid, 7-[4-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]ethynyl]-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



RN 856677-37-7 CAPLUS
CN 3-Quinolinecarboxylic acid, 7-[4-[2-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]ethyl]-4-hydroxy-1-piperidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB New antiprotozoals active against Philasterides dicentrarchi, the causative agent of scuticociliatosis in farmed turbot and Black Sea bass-bream, have been synthesized and tested. The most active compds. possess a piperazine ring, generally N-bonded to the heterocycle, and are 1,8-naphthyridine, pyridothienopyrimidine, and pyridothienotriazine derivs. The pyridothienotriazine I (R1 = 4-methylpiperidino, R2 = 1-piperazinyl) presents the same activity (LD = 0.8/1.5 mg L-1) as the well-known antiparasitics niclosamide and oxyclozanide.
AN 2003:236103 CAPLUS Full-text
DN 139:197457
TI Piperazine N-substituted naphthyridines, pyridothienopyrimidines and pyridothienotriazines: new antiprotozoals active against Philasterides dicentrarchi
AU Quintela, Jose M.; Peinador, Carlos; Gonzalez, Liliana; Iglesias, Raul; Parama, Anabel; Alvarez, Francisca; Sanmartin, Manuel L.; Riguera, Ricardo
CS Facultad de Ciencias, Departamento de Quimica Fundamental e Industrial, Universidad de La Coruna, La Coruna, 15071, Spain
SO European Journal of Medicinal Chemistry (2003), 38(3), 265-275
CODEN: EJMCA5; ISSN: 0223-5234
PB Editions Scientifiques et Medicales Elsevier
DT Journal
LA English
OS CASREACT 139:197457
IT 583051-27-8P 583051-28-9P
RL: AGR (Agricultural use); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinyl-subtituted naphthyridines, pyridothienopyrimidines, and pyridothienotriazines as antiprotozoals active against Philasterides dicentrarchi)
RN 583051-27-8 CAPLUS
CN 1,8-Naphthyridine-3,6-dicarbonitrile, 2-ethoxy-4-phenyl-7-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



RN 583051-28-9 CAPLUS
CN 1,8-Naphthyridine-3,6-dicarbonitrile,
2-ethoxy-4-phenyl-7-[4-(phenylmethyl)-1-piperidinyl]- (CA INDEX NAME)



OSC.G 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I

AB Cytokine formation inhibitors contain (I; R1 = C1-6 alkyl; R2, R3, R4, R6 = H, etc.; R5 = halogen, etc.; X = H, etc.; A = N, etc.; m = 2 or 3; Y = Oh; Z = C, etc.) and their salts for treatment of cytokines-related diseases. The cytokines include IL-1 to IL-15, TNF-α, M-CAF, RANTES, MIP-1, SCF, GM-CSF, G-CSF, M-CSF, erythropoietin, thrombopoietin, interferon, NGF, TGF-β, PDGF, EGF, and LIF.
AN 1999:380682 CAPLUS Full-text
DN 131:68133
TI Cytokine formation inhibitors for treatment of cytokines-related diseases
IN Baba, Masanori; Ikeuchi, Kiyoshi; Kimura, Yoichi
PA Daiichi Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11158071	A	19990615	JP 1997-331575	19971202
	JP 3739916	B2	20060125		
PRAI	JP 1997-331575		19971202		

IT 228548-93-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cytokine formation inhibitors for treatment of cytokines-related diseases)
RN 228548-93-4 CAPLUS

CN 3-Quinolinecarboxylic acid, 8-(difluoromethoxy)-6-fluoro-1,4-dihydro-4-oxo-7-(4-phenyl-1-piperidinyl)-1-[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- (CA INDEX NAME)



L11 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2010 ACS on STN
GI



I



II

AB The title compds. [I; R = H, Br, Cl, F, NO2; R1 = H, Cl, F, R2R3N; R2, R3 = alkyl, hydroxyalkyl; R2R3N = (un)substituted heterocyclyl] (89 compds.) were prepared Thus, CH2(CO2Et)2 underwent Grignard benzoylation with 2,4,5-Cl2FC6H2COCl to give 2,4,5-Cl2FC6H2COCH(CO2Et)2. This was decarboxylated and condensed with HC(OEt)3 to give 2,4,5-Cl2FC6H2COC(:CHOEt)CO2Et which was treated with cyclopropylamine and cyclized to give I (R = F, R1 = Cl). This was treated with piperazine to give II.HCl. On rice plants 0.025% II.HCl gave 80% protection against damage by Xanthomonas oryzae.

AN 1984:611165 CAPLUS Full-text
DN 101:211165
OREF 101:31999a,32002a
TI Microbicidal composition based on quinolonecarboxylic acid
IN Grohe, Klaus; Petersen, Uwe; Kuck, Karl Heinz
PA Bayer A.-G. , Fed. Rep. Ger.
SO Ger. Offen., 60 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3248507	A1	19840705	DE 1982-3248507	19821229

	US 4563459	A	19860107	US 1983-561441	19831214
	EP 113091	A1	19840711	EP 1983-112720	19831217
	EP 113091	B1	19860730		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
	AT 21011	T	19860815	AT 1983-112720	19831217
	AU 8322863	A	19840705	AU 1983-22863	19831223
	AU 563747	B2	19870723		
	CA 1232198	A1	19880202	CA 1983-444242	19831223
	IL 70540	A	19870731	IL 1983-70540	19831226
	BR 8307166	A	19840807	BR 1983-7166	19831227
	DK 8306038	A	19840630	DK 1983-6038	19831228
	ZA 8309647	A	19840829	ZA 1983-9647	19831228
	HU 32709	A2	19840928	HU 1983-4498	19831228
	HU 194482	B	19880229		
	JP 59130802	A	19840727	JP 1983-252506	19831229
PRAI	DE 1982-3248507	A	19821229		
	EP 1983-112720	A	19831217		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 101:211165; MARPAT 101:211165

IT 93106-79-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 93106-79-7 CAPLUS

CN 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-phenyl-1-piperidinyl)- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)